Ropinirole

CNS Drugs

Volumn 8, Issue 4, 1997, Pages 335-341

  Dechant, Kerry L ^a   Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; ROPINIROLE; SELEGILINE;

HEADACHE; HUMAN; INSOMNIA; MOTOR PERFORMANCE; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; VERTIGO; VOMITING;

EID: 0030770215     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199708040-00006     Document Type: Review

References (26)

1. Montrastruc J-L, Rascol O, Senard J-M. New directions in the drug treatment of Parkinson's disease. Drugs Aging 1996; 4 (3): 169-84
2. Calne DB. Treatment of Parkinson's disease. New Engl J Med 1993; 329 (14): 1021-7
3. Uitti RJ, Ahlskog JE. Comparative review of dopamine receptor agonists in Parkinson's disease. CNS Drugs 1996 May; 5: 369-88
4. 2 agonist. Pharmacol Biochem Behav 1991 Jan; 38: 147-54
5. 2 agonisi, in anaesthetised cats. Eur J Pharmacol 1990 Jan 17; 175: 333-40
6. 2-like receptor agonist. Eur J Pharmacol 1994 Nov 14; 265: 17-26
7. Pearce RKB, Banerji T, Jenner P, et al. Effects of repeated treatment with l-dopa, bromocriptine and ropinirole in drug naive MPTP-treated common marmosets [abstract 37P]. Br J Pharmacol 1996; 118 Suppl.
8. 2-dopaminergic agonist ropinirol on supine resting and stimulated circulatory and neuroendocrine variables in healthy volunteers. Arzneimittel Forschung 1990 Jan; 40: 7-13
9. 2-receptor agonist. Br J Clin Pharmacol 1989 Oct; 28: 435-41
10. 2-receptor agonist. Br J Clin Pharmacol 1991 Oct; 32: 483-8
11. Boothman BR, Spokes EG. Pharmacokinetic data for ropinirole [letter: comment]. Lancet 1990 Sep 29; 336: 814
12. Jenner P, Tulloch I. The preclinical pharmacology of ropinirole - receptor interactions, antiparkinsonian activity and potential to induce dyskinesia. In: Olanow CW, Obeso JA, editors. Beyond the decade of the brain. Dopamine agonists in early Parkinson's disease ed. Vol. 2. Royal Tunbridge Wells, Kent: Wells Medical Limited, 1997: 115-27
13. Beerahee A, Nichols AI, Aluri J, et al. Population pharmacokinetics of ropinirole in patients with Parkinson's disease [abstract]. Br J Clin Pharmacol 1997 May; 43: 556P-7P
14. Taylor AC, Beerahee A, Cyronak M, et al. Lack of a pharmacokinetic interaction between ropinirole and l-dopa in Parkinsonian patients [abstract]. Pharmacotherapy 1996 May-Jun; 16: 512-3
15. Taylor AC, Cyronak M, Citerone RD, et al. Lack of a pharmacokinetic interaction between ropinirole and theophylline in parkinsonian patients [abstract]. Br J Clin Pharmacol 1997 May; 43: 555P-6P
16. Thalamus C, Rayet S, Brefel C, et al. Effect of food cm the pharmacokinetics of ropinirole in patients with Parkinson's disease [abstract]. Mov Disord 1996; 11 Suppl. 1: 138
17. Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's disease. Neurology. In press
18. Kreider MS, Wilson-Lynch K, Gardiner D, et al. A double-blind. placebo-controlled extension study to evaluate the 12-month efficacy and safely of ropinirole in early Parkinson's disease [abstract]. Presented at the 49th Annual Meeting of the American Academy of Neurology: 1997 Apr 12-19: Boston
19. Brooks DJ, Torjanski N, Burn DJ. Ropinirole in the symptomatic treatment of Parkinson's disease. J Neural Transm 1995; 45 Suppl.: 231-8
20. Korczyn AD, Brooks DJ, Brunt ER, et al. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. Mov Disord. In press
21. Rascol O, Brooks DJ, Brunt ER, et al. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year L-dopa-conrolled study. Mov Disord. In press
22. Rascol O, Lees AJ, Senard JM, et al. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol 1996 Jun; 19: 234-45
23. Perez-Aharon J, Abbot RJ, Playfer JR, et al. Ropinirole, a placebo-controlled study of efficacy as adjunct therapy in parkinsonian patients not optimally controlled on L-dopa [abstract]. Neurology 1994 Apr; 44 Suppl. 2: 244
24. Sagar H. Anti-Parkinson efficacy (L-dopa sparing effect) of ropinirole vs placebo as adjunct therapy in parkinsonian patients not opimally controlled on L-dopa [abstract]. New Trends Clin Neuropharmacol 1994; 8 (1): 321
25. Kreider M, Knox S, Gardiner D, et al. A multicenter double-blind study of ropinirole as an adjunct to L-dopa in Parkinson's disease [abstract]. Neurology 1996 Feb; 46 Suppl. 2: 475
26. Ropinirole 043 study group. A double-blind comparative study of ropinirole vs bromocriptine in the treatment of Parkinsonian patients not optimally controlled on l-dopa [abstract P705]. Mov Disord 1996; 11 Suppl. 1: 188